感染性腹主动脉瘤:EVAR术后再感染率高于开放修复
EVAR组再感染率显著高于OAR组(RR 2.42,95%CI 1.80-3.27,P<.0001),但围术期死亡、1年死亡率及再入院或再干预无显著差异。
要点
- EVAR治疗感染性腹主动脉瘤的再感染风险是OAR的2.42倍。
- 两组围术期死亡、1年死亡率及再入院或再干预无显著差异。
- EVAR术后应加强移植物和感染监测。
核心结论
- EVAR治疗感染性腹主动脉瘤的再感染率显著高于OAR,但围术期和1年生存相似。
主要发现
- EVAR组再感染 crude 率为13.6%(95%CI 8.8%-18.5%),感染相关破裂或死亡为4.9%(95%CI 1.8%-8.0%)。
- EVAR组再感染风险显著高于OAR组(RR 2.42,95%CI 1.80-3.27,P<.0001,I2=0%)。
- 感染相关破裂或死亡(RR 1.51,95%CI 0.70-3.23,P=.29)、围术期死亡(RR 0.80,95%CI 0.39-1.65,P=.55)、1年死亡率(HR 1.12,95%CI 0.97-1.28,P=.13)及再入院或再干预(RR 1.16,95%CI 0.74-1.82,P=.52)组间无显著差异。
关键数值与推荐
- EVAR使用率从2010-2015年的13.8%增至2016-2020年的32.4%(P<.0001)。
- OAR中手术清创均实施,原位重建占82.2%,大网膜瓣占51.5%。
- EVAR中开窗、分支或联合内脏去分支技术占6.1%。
临床怎么用
- 选择EVAR治疗感染性腹主动脉瘤时需权衡再感染风险。
- EVAR术后应加强移植物和感染监测。
局限性
- 纳入研究均为观察性研究,存在选择偏倚可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Controversy has continued regarding the use of endovascular aneurysm repair (EVAR) vs open aneurysm repair (OAR) for infected abdominal aortic aneurysms (AAAs). In the present study, we investigated the comparative outcomes of EVAR and OAR for the treatment of infected AAAs. METHODS: We conducted a systematic review and meta-analysis using the MEDLINE and EMBASE databases through May 2021. We included studies that had described both EVAR and OAR for the treatment of infected AAAs. The primary endpoints were the rates of recurrent infection and related rupture and/or death. Perioperative and 1-year mortality and readmissions and reinterventions were also analyzed. RESULTS: Fourteen observational studies describing a total of 1203 patients (EVAR, 359 [29.8%]; OAR, 844 [70.2%]) were eligible for qualitative analysis. The baseline characteristics included diabetes mellitus (33.2%), fever at presentation (71.6%), rupture at diagnosis (26.1%), and positive blood cultures (52.5%). The mean follow-up period ranged from 12 to 40 months. The use of EVAR became more prevalent in recent years (2016-2020, 32.4%) compared with the former period (2010-2015, 13.8%; P < .0001). Fenestrated, branched, or concomitant visceral debranching EVAR was performed in 6.1% of cases. In OAR, surgical debridement was consistently performed, and in situ reconstruction was applied in 82.2% and an omental flap in 51.5%. In nine studies considered for quantitative analysis, the patients' background (EVAR, n = 264; OAR, n = 274) were statistically balanced. The crude rates of recurrent infection and related rupture or death were 13.6% (95% confidence interval [CI], 8.8%-18.5%) and 4.9% (95% CI 1.8%-8.0%), respectively. The pooled analyses depicted significantly higher rates of recurrent infection after EVAR than after OAR (relative risk [RR], 2.42; 95% CI, 1.80-3.27; P < .0001; I2 = 0%). Recurrent infection-related rupture or death (RR, 1.51; 95% CI, 0.70-3.23; P = .29; I2 = 0%), perioperative death (RR, 0.80; 95% CI, 0.39-1.65; P = .55; I2 = 35%), 1-year mortality (hazard ratio, 1.12; 95% CI, 0.97-1.28; P =.13; I2 = 0%), and readmission or reintervention (RR, 1.16; 95% CI, 0.74-1.82; P =.52; I2 = 0%) were not significantly different statistically between the two groups. Funnel plots showed no evidence of publication bias. Sensitivity analyses of leave-one-out meta-analysis confirmed higher rates of recurrent infection after EVAR. CONCLUSIONS: EVAR has become more prevalent as the initial treatment of infected AAAs. Although operative and 1-year survival were similar between OAR and EVAR groups, recurrent infection was more frequent after EVAR. This limitation should be weighed in selecting patients for EVAR in infected AAAs. Postoperative graft and infection surveillance are critical, especially after EVAR.
引用
- Shirasu T, Kuno T, Yasuhara J, et al. Meta-analysis finds recurrent infection is more common after endovascular than after open repair of infected abdominal aortic aneurysm. J Vasc Surg. 2021. PMID: 34500028. doi:10.1016/j.jvs.2021.07.240
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。